Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091999 · ClinicalTrials.gov registry record · Phase 1
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
A Phase 1 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT02091999 is a Phase 1 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 213 participants.
The verdict
NCT02091999, a Phase 1 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of enfortumab vedotin as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.
Interventions
- DRUG enfortumab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2014-05-14 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091999
The ClinicalTrials.gov registry entry for NCT02091999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which enfortumab vedotin is the first listed.
NCT02091999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091999 about?
NCT02091999 is a clinical study titled "A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4". The purpose of this study is to evaluate the safety and pharmacokinetics of enfortumab vedotin as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.
What is the current status of trial NCT02091999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2014-05-14. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT02091999?
The interventions under investigation include: enfortumab vedotin (DRUG).
Who is sponsoring clinical trial NCT02091999?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.